NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
December 05, 2023 09:00 ET | NeuroMetrix, Inc.
NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain.
AlgoTx Announces First Patients Dosed in US and European Arms of Phase II Clinical Trial of ATX01 in Rare Disease Erythromelalgia
September 12, 2023 03:00 ET | AlgoTX
PARIS, Sept. 12, 2023 (GLOBE NEWSWIRE) --  AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing targeted, first-in-class therapeutics for peripheral neuropathic pain,...
Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)
May 31, 2023 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial...
CIPN Market: 5.4% CAGR for Chemotherapy-Induced Peripheral Neuropathy Market Worth $1.17 Billion, Globally, by 2028: The Insight Partners
May 26, 2022 15:07 ET | The Insight Partners
New York, May 27, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Chemotherapy-Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global...
Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology
May 06, 2021 09:00 ET | Neuropathix, Inc.
DOYLESTOWN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today the...
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting
December 10, 2020 08:43 ET | Trevena Inc.
-- Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P1 receptor without associated lymphopenia IND filing on track for...
Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company’s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain
January 14, 2020 09:00 ET | Kannalife, Inc.
DOYLESTOWN, Penn., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of...
Kannalife Inc. Publishes New Research on Chemotherapy-Induced Peripheral Neuropathy
May 21, 2019 09:00 ET | Kannalife, Inc.
DOYLESTOWN, Pa., May 21, 2019 (GLOBE NEWSWIRE) -- Kannalife, Inc. (OTC:KLFE), Kannalife (“Kannalife” or “the Company”), a biopharmaceutical company leading innovation in research, development and...
PledPharma presenter
PledPharma presenterar läkemedelskandidaten PledOx® fas III-program på global cancerkonferens
January 17, 2019 02:00 ET | PledPharma AB
Stockholm, 17 januari 2019. PledPharma AB (publ) meddelar att bolagets globala fas III-program, POLAR, för PledOx® har accepterats för poster-presentation på den globala konferensen Gastrointestinal...
PledPharma presents
PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium
January 17, 2019 02:00 ET | PledPharma AB
Stockholm, January 17, 2019. PledPharma AB (publ) announces that the company’s global phase III program, POLAR, has been accepted for a poster presentation during the Gastrointestinal (GI) Cancers...